Roche’s pharma sales grow 7% but pipeline trimmed down - Pharmaceutical Technology

Several drugs fuelled Roche’s sales for the first nine months reflecting the company’s diverse commercial portfolio. Several drugs fuelled Roche’s sales for the first nine months reflecting the company’s diverse commercial portfolio. The Swiss company has made a string of acquisitions and license agreements already this year to bolster its pipeline. Credit: Konektus Photo/Shutterstock.com. Roche posted a healthy 7% growth for its pharmaceutical division in the first nine months of 2026, though the drugmaker discontinued several clinical programmes amid asset prioritisation. Sales for Roche’s medicines reached CHF 36.2bn ($44bn) for the period, denoting just under 80% of the company’s total…

Source: Pharmaceutical Technology